Back to School: How biopharma can reboot drug development. Access exclusive analysis here

RetinoStat: Phase I suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the impurities are derived

Read the full 380 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers